Ixazomib as a Replacement for Carfilzomib and Bortezomib for Multiple Myeloma Patients
Status:
Active, not recruiting
Trial end date:
2020-09-01
Target enrollment:
Participant gender:
Summary
The goal of this clinical research study is to evaluate the safety and effectiveness (good
and bad effects) of ixazomib given as part of a combination therapy to treat subjects with
relapsed (subjects whose disease came back) or refractory (subjects whose disease did not
respond to past treatment) multiple myeloma. More specifically, the study is focused on
subjects who were previously treated with bortezomib (Velcade®) or carfilzomib (Kyprolis®)
and showed worsening of their myeloma while receiving either one of these drugs in
combination therapy. This study is a Phase I/II. Ixazomib is an investigational drug, which
means that ixazomib is currently being tested and is not yet approved by the United States
Food and Drug Administration (FDA) for subjects with relapsed or refractory multiple myeloma.
Ixazomib is a new study drug that belongs to the same class as bortezomib and carfilzomib;
however, unlike bortezomib and carfilzomib, ixazomib is taken by mouth. Current studies
investigating ixazomib are demonstrating that it is as safe as bortezomib and effective for
the treatment of multiple myeloma both on its own and in combination with other multiple
myeloma medications, such as lenalidomide and dexamethasone, or prednisone and melphalan.